Business

Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference

LONDON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a

articleKiniksa Pharmaceuticals International, PlcNovember 26, 20245/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-present-7th-annual-evercore-isi-healthconx-conference-2024-11
Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference

About this update from Kiniksa Pharmaceuticals International, Plc

[{"type":"text","content":"LONDON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024 at 9:35 a.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event. About KiniksaKiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com. Every Second Counts! ® Kiniksa Investor ContactJonathan Kirshenbaum (781) [email protected] Kiniksa Media ContactTyler Gagnon(781) [email protected] \nSource: Kiniksa Pharmaceuticals, Ltd.","length":3688,"tagName":"div"}]

More updates from Kiniksa Pharmaceuticals International, Plc